AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39260834 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 260
Study 39260834 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 260
Study 39260834 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 260
Study 39260834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 39260835 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of sentinel lymph node biopsy (SLNB)
Number of subjects: 311
Study 39260848 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal tumour resection
Number of subjects: 0
Study 39260848 — intervention group
Group type: COMPARATOR
Intervention: Tissue biopsy
Number of subjects: 0
Study 39260858 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional wall motion abnormalities (RWMA) detected via transthoracic echocardiography
Number of subjects: 657
Study 39260856 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-17 strategy (secukinumab or ixekizumab)
Number of subjects: 31
Study 39260856 — intervention group
Group type: COMPARATOR
Intervention: Second TNF blocker
Number of subjects: 31
Study 39260878 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter exercise
Number of subjects: 299
Study 39260878 — intervention group
Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronic acid (control group)
Number of subjects: 299
Study 39260927 — intervention group
Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg
Number of subjects: 228
Study 39260927 — intervention group
Group type: EXPERIMENTAL
Intervention: Evogliptin 10 mg
Number of subjects: 228
Study 39260927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 39260929 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Number of subjects: 1222
Study 39260929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1222
Study 39260960 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable TAVR valves with no THV underexpansion or eccentricity (Group 1)
Number of subjects: 229
Study 39260960 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable TAVR valves with underexpansion or eccentricity (Group 2)
Number of subjects: 229
Study 39260960 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable TAVR valves with both underexpansion and eccentricity (Group 3)
Number of subjects: 229
Study 39260960 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium distribution assessed using CT
Number of subjects: 229
Study 39260960 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of patients with type 1 BAVs
Number of subjects: 229
Study 39260962 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided decongestion
Number of subjects: 232
Study 39261226 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted group (with machine learning predictions)
Number of subjects: 5071
Study 39261226 — intervention group
Group type: COMPARATOR
Intervention: Unassisted group (without machine learning predictions)
Number of subjects: 5071
Study 39261236 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide with docetaxel
Number of subjects: 157
Study 39261236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-docetaxel ctDNA detection
Number of subjects: 157
Study 39261236 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence/rise of ctDNA at C2D1
Number of subjects: 157
Study 39261265 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy for pancreatic stones (P-ESWL)
Number of subjects: 2071
Study 39261417 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg once every 3 weeks
Number of subjects: 262
Study 39261446 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab every 4 or 8 weeks (Q4W/Q8W)
Number of subjects: 1120
Study 39261446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1120
Study 39261446 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 1120
Study 39261482 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 third dose
Number of subjects: 0
Study 39261512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (CMR)
Number of subjects: 100
Study 39261512 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers testing immunological response and coagulopathy
Number of subjects: 100
Study 39261512 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent symptoms
Number of subjects: 100
Study 39261512 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive serology for prior SARS-CoV-2 infection
Number of subjects: 100
Study 39261671 — intervention group
Group type: COMPARATOR
Intervention: lysergic acid diethylamide (LSD)
Number of subjects: 28
Study 39261671 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine
Number of subjects: 28
Study 39261671 — intervention group
Group type: COMPARATOR
Intervention: 3,4-methylenedioxymethamphetamine (MDMA)
Number of subjects: 28
Study 39261671 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 39261786 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diet combined with mindfulness cognitive therapy (educational group-based sessions on Mediterranean-type diet and mindfulness principles)
Number of subjects: 250
Study 39261786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 250
Study 39261790 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic real-time feedback strategy (KRTF) with an inertial sensor
Number of subjects: 59
Study 39261790 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods group (G1)
Number of subjects: 59
Study 39261815 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (group and individual) for four months, including pelvic floor muscle training (PFMT) recommended daily
Number of subjects: 41
Study 39261815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 41
Study 39261815 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 41
Study 39261815 — intervention group
Group type: EXPERIMENTAL
Intervention: Group pain management course emphasizing exercise training as self-management
Number of subjects: 41
Study 39261900 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-monthly monitoring of serum neurofilament light chain (sNfL) in addition to usual care (group A)
Number of subjects: 915
Study 39261900 — intervention group
Group type: COMPARATOR
Intervention: Usual care with 6- or 12-monthly visits (group B)
Number of subjects: 915
Study 39261919 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (DEC) + all-trans retinoic acid (ATRA)
Number of subjects: 1
Study 39261919 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study 39261949 — intervention group
Group type: EXPERIMENTAL
Intervention: Active repetitive transmagnetic stimulation (rTMS)
Number of subjects: 0
Study 39261949 — intervention group
Group type: COMPARATOR
Intervention: Sham repetitive transmagnetic stimulation (rTMS)
Number of subjects: 0
Study 39261953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy to address maladaptive thought patterns and behaviors around social connection
Number of subjects: 102
Study 39261953 — intervention group
Group type: EXPERIMENTAL
Intervention: Social prescribing intervention to connect participants with social opportunities and develop supportive social networks
Number of subjects: 102
Study 39261953 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 102
Study 39261967 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers and Babies Virtual Group (MB-VG)
Number of subjects: 300
Study 39261967 — intervention group
Group type: COMPARATOR
Intervention: Delayed receipt of the intervention (Control)
Number of subjects: 300
Study 39262319 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-based management (n=46)
Number of subjects: 91
Study 39262319 — intervention group
Group type: COMPARATOR
Intervention: MAP-based management (n=45)
Number of subjects: 91
Study 39262426 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger maximal lifetime brain growth (MLBG)
Number of subjects: 383
Study 39262426 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 383
Study 39262580 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Postural Re-education (GPR) self-management program
Number of subjects: 41
Study 39262902 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy (MDMA-AT)
Number of subjects: 0
Study 39262903 — intervention group
Group type: EXPERIMENTAL
Intervention: Shi's manual therapy (SMT)
Number of subjects: 106
Study 39262903 — intervention group
Group type: COMPARATOR
Intervention: Merislon (Betahistine Mesilate Tablets)
Number of subjects: 106
Study 39263280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal esketamine 2 mg/kg (Group K)
Number of subjects: 180
Study 39263280 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine 1 mg/kg and dexmedetomidine 1 µg/kg (Group KD1)
Number of subjects: 180
Study 39263280 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine 0.5 mg/kg and dexmedetomidine 2 µg/kg (Group KD2)
Number of subjects: 180
Study 39263388 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-Based Training for Musculoskeletal Health Promotion
Number of subjects: 0
Study 39263597 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-nightly sodium oxybate (ON-SXB, FT218)
Number of subjects: 130
Study 39263597 — intervention group
Group type: COMPARATOR
Intervention: Twice-nightly immediate-release (IR) oxybate
Number of subjects: 130
Study 39263755 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy (LTME)
Number of subjects: 1078
Study 39263755 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy (OTME)
Number of subjects: 1078
Study 39263755 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery (RTME)
Number of subjects: 1078
Study 39263755 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal surgery (TaTME)
Number of subjects: 1078
Study 39263892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) with nab-paclitaxel plus systemic gemcitabine, cisplatin, and durvalumab (gem/cis/durva)
Number of subjects: 0
Study 39263892 — intervention group
Group type: COMPARATOR
Intervention: Systemic treatment comprising gemcitabine, cisplatin, and durvalumab (gem/cis/durva)
Number of subjects: 0
Study 39264028 — intervention group
Group type: EXPERIMENTAL
Intervention: Uroflowmetry curve interpretation by four investigators
Number of subjects: 296
Study 39264028 — intervention group
Group type: EXPERIMENTAL
Intervention: Uroflowmetry curve interpretation by each investigator (intraterater reliability)
Number of subjects: 296
Study 39264062 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ultralow anterior resection using a new articulating device
Number of subjects: 0
Study 39264108 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth intervention group (12 interactive modules on PA, DB, and sleep delivered weekly)
Number of subjects: 206
Study 39264108 — intervention group
Group type: COMPARATOR
Intervention: Control group (weekly brochures on PA, DB, and sleep recommendations)
Number of subjects: 206
Study 39264399 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab
Number of subjects: 0
Study 39264438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 70 µg/day (2800 IU)
Number of subjects: 86
Study 39264438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 39264438 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drugs (ATD)
Number of subjects: 86
Study 39264499 — intervention group
Group type: EXPERIMENTAL
Intervention: CINDERELLA APProach (AI cloud-based platform)
Number of subjects: 0
Study 39264499 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 0
Study 39264499 — intervention group
Group type: EXPERIMENTAL
Intervention: CINDERELLA APProach
Number of subjects: 0
Study 39264503 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of rosuvastatin
Number of subjects: 80
Study 39264503 — intervention group
Group type: COMPARATOR
Intervention: 40 mg of atorvastatin
Number of subjects: 80
Study 39264535 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenohumeral hydrodistension combined with bursal injection
Number of subjects: 36
Study 39264535 — intervention group
Group type: COMPARATOR
Intervention: Glenohumeral hydrodistension alone
Number of subjects: 36
Study 39264599 — intervention group
Group type: EXPERIMENTAL
Intervention: MYL-1701P (0.5-mg vial) every 4 weeks for 5 consecutive intravitreal injections, followed by every 8 weeks through week 52
Number of subjects: 355
Study 39264599 — intervention group
Group type: COMPARATOR
Intervention: Reference aflibercept every 4 weeks for 5 consecutive intravitreal injections, followed by every 8 weeks through week 52
Number of subjects: 355
Study 39264599 — intervention group
Group type: EXPERIMENTAL
Intervention: MYL-1701P
Number of subjects: 355
Study 39264599 — intervention group
Group type: COMPARATOR
Intervention: Reference aflibercept
Number of subjects: 355
Study 39264623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg)
Number of subjects: 1465
Study 39264623 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg)
Number of subjects: 1465
Study 39264640 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonotopic map
Number of subjects: 26
Study 39264640 — intervention group
Group type: COMPARATOR
Intervention: Conventional map
Number of subjects: 26
Study 39264682 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect labeling
Number of subjects: 0
Study 39264682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Number of subjects: 0
Study 39264682 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 39264960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) / Chloroquine (CQ)
Number of subjects: 4652
Study 39264960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4652
Study 39265124 — intervention group
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan (Dato-DXd) 6 mg/kg once every 3 weeks
Number of subjects: 732
Study 39265124 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice of chemotherapy (ICC)
Number of subjects: 732
Study 39265161 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine diagnostic tools
Number of subjects: 250
Study 39265161 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary diagnostic devices
Number of subjects: 250
Study 39265161 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Evaluation Questionnaire, Physical Activity Questionnaire, sugar intake assessment, Constitution in Chinese Medicine Questionnaire, radial pulse diagnosis, and tongue diagnosis
Number of subjects: 250
Study 39265169 — intervention group
Group type: EXPERIMENTAL
Intervention: AG-348 (mitapivat), a pyruvate kinase activator
Number of subjects: 0
Study 39265169 — intervention group
Group type: EXPERIMENTAL
Intervention: AG-348 (mitapivat)
Number of subjects: 0
Study 39265173 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg)
Number of subjects: 150
Study 39265173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 39265255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis (AFO)
Number of subjects: 10
Study 39265255 — intervention group
Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 10
Study 39265255 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking
Number of subjects: 10
Study 39265255 — intervention group
Group type: COMPARATOR
Intervention: Overground walking
Number of subjects: 10
Study 39265466 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin (PC) - 6 cycles of P 175 mg/m2 and C AUC=6 IV every 3 weeks
Number of subjects: 63
Study 39265466 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin, Etoposide, and Cisplatin (BEP) - 4 cycles of B 20 units/m2 IV push day 1, E 75 mg/m2 IV days 1-5, and Cisplatin 20 mg/m2 IV days 1-5 every 3 weeks
Number of subjects: 63
Study 39265579 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously every 21 days until disease progression or unacceptable toxicity.
Number of subjects: 7
Study 39265599 — intervention group
Group type: EXPERIMENTAL
Intervention: Plinabulin plus docetaxel (n=278)
Number of subjects: 559
Study 39265599 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus placebo (n=281)
Number of subjects: 559
Study 39265613 — intervention group
Group type: EXPERIMENTAL
Intervention: fedratinib 400 mg per day
Number of subjects: 201
Study 39265613 — intervention group
Group type: COMPARATOR
Intervention: best available therapy (BAT)
Number of subjects: 201
Study 39265613 — intervention group
Group type: EXPERIMENTAL
Intervention: fedratinib
Number of subjects: 201
Study 39265613 — intervention group
Group type: COMPARATOR
Intervention: BAT
Number of subjects: 201
Study 39265782 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT1VATE (five-week ACT group telehealth intervention)
Number of subjects: 250
Study 39265782 — intervention group
Group type: COMPARATOR
Intervention: Usual care (diabetes self-management education and support)
Number of subjects: 250
Study 39265784 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor-cognitive training (dual-tasks) for 20 weeks
Number of subjects: 0
Study 39265915 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies addressing barriers such as staff availability, knowledge, and attitudes.
Number of subjects: 57
Study 39265915 — intervention group
Group type: EXPERIMENTAL
Intervention: National policy changes such as increased financing and public reporting of quality metrics.
Number of subjects: 57
Study 39266012 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Number of subjects: 30
Study 39266012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 39266045 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate surgery
Number of subjects: 67
Study 39266045 — intervention group
Group type: COMPARATOR
Intervention: Selective surgery
Number of subjects: 67
Study 39266205 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy using an intrauterine manipulator
Number of subjects: 1030
Study 39266205 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy without an intrauterine manipulator
Number of subjects: 1030
Study 39266213 — intervention group
Group type: EXPERIMENTAL
Intervention: HERV-E TCR-transduced T cells (HERV-E T cells)
Number of subjects: 0
Study 39266213 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39266309 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg QD orally for 3 days before surgery and 0.5 mg QOD for 10 days after surgery)
Number of subjects: 768
Study 39266309 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch tablets for the same time and dosage)
Number of subjects: 768
Study 39266309 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 768
Study 39266309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 768
Study 39266308 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranodal administration of tolDCs loaded with heat shock protein 70-derived peptide mB29a, two intranodal injections of 5×10 (dosage not fully specified)
Number of subjects: 0
Study 39266314 — intervention group
Group type: EXPERIMENTAL
Intervention: PRALIMAP-INÈS intervention
Number of subjects: 852
Study 39266314 — intervention group
Group type: EXPERIMENTAL
Intervention: Check-up visit by clinical research nurse
Number of subjects: 852
Study 39266314 — intervention group
Group type: EXPERIMENTAL
Intervention: Semistructured interview by sociologist
Number of subjects: 852
Study 39266323 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 204
Study 39266323 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin succinate
Number of subjects: 204
Study 39266535 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 160
Study 39266535 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 160
Study 39266619 — intervention group
Group type: EXPERIMENTAL
Intervention: DP303c administered intravenously every 3 weeks at doses of 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 3.0 mg/kg, and 4.0 mg/kg.
Number of subjects: 94
Study 39266619 — intervention group
Group type: EXPERIMENTAL
Intervention: DP303c
Number of subjects: 94
Study 39266747 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination of HIV-1 broadly neutralizing antibodies (bNAbs)
Number of subjects: 0
Study 39266747 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy or cocktail of two antibodies
Number of subjects: 0
Study 39266862 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Chinese herbal medicine (chemo+CHM)
Number of subjects: 180
Study 39266862 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy combined with placebo (chemo+placebo)
Number of subjects: 180
Study 39266891 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive text messaging (ITM) for alcohol use
Number of subjects: 188
Study 39266891 — intervention group
Group type: COMPARATOR
Intervention: Behavioral intervention (MI)
Number of subjects: 188
Study 39266891 — intervention group
Group type: COMPARATOR
Intervention: Extended intervention (EI)
Number of subjects: 188
Study 39266891 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (BI)
Number of subjects: 188
Study 39266938 — intervention group
Group type: EXPERIMENTAL
Intervention: Online biopsychobehavioral rehabilitation study including phosphodiesterase-5 inhibitors, sexual aids, pelvic floor exercise regimen, video, guide to good gay sex, and coaching.
Number of subjects: 401
Study 39266938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual aids (including vacuum pump, anal dilators, and penile constriction rings), masturbation, and pelvic floor exercises.
Number of subjects: 401
Study 39266938 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified).
Number of subjects: 401